"HM Sanchinarro es un hospital general médico-quirúrgico con 35.000 m2 construidos y cuenta con cuatro policlínicos de consultas externas. Dispone de Urgencias 24 horas y de todas las especialidades médicas y quirúrgicas, con la excepción de Obstetricia, Neonatología y Cirugía Cardiaca; un área de consultas y 12 quirófanos de última generación como el dotado con el robot quirúrgico Da Vinci, con el que HM Hospitales inició su Programa de Cirugía Robótica, que avanza en la cirugía mínimamente invasiva para conseguir los mejores resultados médicos y una recuperación más rápida de los pacientes. El Servicio de Diagnóstico por Imagen de HM Sanchinarro está dotado de equipos de radiología más modernos."

During the past decade, Hospital Universitario HM Sanchinarro conducted 170 clinical trials. In the 10-year time frame, 170 clinical trials started and 44 clinical trials were completed, i.e. on average, 25.9% percent of trials that started reached the finish line to date. In the past 5 years, 99 clinical trials started and 34 clinical trials were completed. i.e. 34.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario HM Sanchinarro" #1 sponsor was "Pfizer" with 21 trials, followed by "Janssen Research & Development, LLC" with 14 trials sponsored, "Eli Lilly and Company" with 13 trials sponsored, "Incyte Corporation" with 9 trials sponsored and "PharmaMar" with 9 trials sponsored. Other sponsors include 129 different institutions and companies that sponsored additional 95 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario HM Sanchinarro" #1 collaborator was "Merck Sharp & Dohme LLC" with 10 trials as a collaborator, "Apices Soluciones S.L." with 6 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 6 trials as a collaborator, "Astellas Pharma Inc" with 5 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 4 trials as a collaborator. Other collaborators include 67 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario HM Sanchinarro" are "Breast Cancer" (11 trials), "Multiple Myeloma" (7 trials), "Neoplasms" (7 trials), "Metastatic Breast Cancer" (5 trials) and "Solid Tumor" (5 trials). Many other conditions were trialed in "Hospital Universitario HM Sanchinarro" in a lesser frequency.

Most popular intervention types in "Hospital Universitario HM Sanchinarro" are "Drug" (171 trials), "Biological" (20 trials), "Other" (10 trials), "Radiation" (7 trials) and "Device" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Pembrolizumab" (14 trials), "Carboplatin" (8 trials), "Dexamethasone" (8 trials) and "Abemaciclib" (6 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario HM Sanchinarro" are 172 trials for "All" genders, 15 trials for "Male" genders and 13 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Universitario HM Sanchinarro". 1 are not yet recruiting, 55 are recruiting, 48 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 72 completed trials in Hospital Universitario HM Sanchinarro, undefined suspended trials, and 15 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario HM Sanchinarro, 62 "Phase 1" clinical trials were conducted, 77 "Phase 2" clinical trials and 55 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 9 trials that are defined as “Not Applicable".

Hospital Universitario HM Sanchinarro has several departments that took part in Clinical trials: "Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia" - 7 trials